The Comparative Medicine Shared Resource (CMSR) provides a broad variety of animal housing, veterinary, and research support services, and, new to this application, patient-derived-xenografts from the Consortium Xenograft Resource (CCXR) for Consortium members. The facility is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and complies with all United States Department of Agriculture (USDA), Public Health Service (PHS), Washington State and local area animal welfare regulations. Comprehensive animal husbandry services are provided for all vertebrate animals used in the Consortium's programs of research. The species of animals housed and supported include fish, mouse, rat, guinea pig and dog. The goals are to provide Consortium members with the highest quality service for research activities including: ? Comprehensive animal husbandry and care; ? Veterinary support; ? Technical support for research activies involving animals; ? Access to patient-derived-xenografts; ? Pathology services; and ? Imaging support in collaboration with the Translational Bioimaging Core Shared Resource. The CMSR seeks opportunties to strengthen or expand services as necessary to further advance the research of the Consortium Programs. For example, the new CCXR service was developed to support the maturation of the Tumor Models developing shared resource, which was was established during the current project period to provide mouse models for understanding the biology of human cancers, particularly focusing on prostate and hematopoietic cancers. To continue expanding access to mouse xenograft models for a wide range of tumors, we recently established a collaboration with the Jackson Laboratories Patient Derived Xenograft (PDX) Consortium, and these activities have been integrated with the CMSR.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-41
Application #
9001915
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2015-02-01
Project End
2019-12-31
Budget Start
2016-01-01
Budget End
2016-12-31
Support Year
41
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications